Where the money went: management itemizes the period's spending into named growth uses tied to business already live
The model's full reasoning — Q4 2017 call → NOWe need to determine if management gives a concrete accounting of where the period's money and effort went, itemizing specific growth-directed uses, and ties those to already-real business. The transcript is from Q4 2017 earnings call. Management discusses progress on lumateperone, ITI-214, ITI-333, etc. They mention spending on clinical trials, regulatory activities, manufacturing, pre-commercial activities. They give a range of expected spending for 2018. But do they itemize what the money was spent on in the period? They mention R&D expenses increased due to clinical trial costs, but they don't give a detailed breakdown. They talk about plans for future trials and pre-commercial activities. They mention hiring a Head of Commercial Development. However, they do not tie spending to specific already-real business like orders or contracts. The spending is for ongoing development and future launches. The question asks if they give a concrete accounting of where the period's money and effort went, itemizing specific growth-directed uses, and tie to already-real business. They mention clinical trial costs, but not specific amounts or specific trials. They talk about pre-commercial activities but not specific commitments. The tone is forward-looking, not an operator's ledger. They don't say "we spent X on this trial that is already enrolling patients" etc. They mention that the long-term safety study is ongoing, but no specifics. They also mention that they expect to spend $180-200 million in 2018, but that's future. The period's spending is not itemized in a concrete way. They do mention that R&D expenses increased due to clinical trial costs, but that's generic. They don't tie to real business. So answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AES | The AES Corporation | Q1 2024 | 2024-05-03 | C+ |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| HP | Helmerich & Payne, Inc. | Q1 2024 | 2024-01-30 | C |
| FSBC | Five Star Bancorp | Q3 2023 | 2023-10-31 | B |
| CMG | Chipotle Mexican Grill, Inc. | Q3 2023 | 2023-10-27 | B+ |
| OXM | Oxford Industries, Inc. | Q2 2023 | 2023-08-31 | C |
| PTLO | Portillo's Inc. | Q2 2023 | 2023-08-05 | B |
| ET | Energy Transfer LP | Q2 2023 | 2023-08-02 | C+ |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| CARS | Cars.com Inc. | Q1 2023 | 2023-05-06 | B |
| M | Macy's, Inc. | Q4 2022 | 2023-03-02 | D |
| CEIX | CONSOL Energy Inc. | Q4 2022 | 2023-02-07 | B |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| CIG | Companhia Energética de Minas Gerais | Q3 2022 | 2022-11-16 | C+ |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| SYY | Sysco Corporation | Q1 2023 | 2022-11-01 | C+ |
| CHE | Chemed Corporation | Q3 2022 | 2022-11-01 | B+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| IT | Gartner, Inc. | Q2 2022 | 2022-08-02 | A |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| CME | CME Group Inc. | Q2 2022 | 2022-07-27 | B |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| KFY | Korn Ferry | Q4 2022 | 2022-06-22 | B |
| FLYW | Flywire Corporation | Q1 2022 | 2022-05-14 | B+ |
| HLIO | Helios Technologies, Inc. | Q1 2022 | 2022-05-10 | C |
| CCRN | Cross Country Healthcare, Inc. | Q1 2022 | 2022-05-04 | B |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| KTB | Kontoor Brands, Inc. | Q3 2021 | 2021-11-04 | A |
| FFWM | First Foundation Inc. | Q3 2021 | 2021-10-26 | B |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| FSS | Federal Signal Corporation | Q1 2018 | 2018-05-12 | A |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
| BCE | BCE Inc. | Q2 2017 | 2017-08-05 | B+ |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
| PSX | Phillips 66 | Q4 2016 | 2017-02-03 | C+ |
| TGI | Triumph Group, Inc. | Q2 2017 | 2016-11-03 | C+ |
| CHDN | Churchill Downs Incorporated | Q2 2016 | 2016-08-04 | C+ |
| LBTYK | Liberty Global's | Q1 2016 | 2016-05-10 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| SON | Sonoco Products Company | Q4 2015 | 2016-02-11 | B |
AES · Q1 2024 → YESThe question is: Does management give a concrete accounting of where the period's money and effort went, itemizing specific growth-directed uses tied to already real business? YES Management itemizes the period’s spending in two places. - Utilities: “our Q1 investment was up nearly 100% from last year, as a result of the new rate structures and investing to improve system resilience and customer experience.” - Renewables: “we have also added almost 600 meg awatts of new projects to our operating portfolio” and “we remain fully on track to add a total of 3.6 gigawatts of new capacity this year” with “92% of the major equipment already on site” for 2024 projects. Both uses are explicitly tied to already-signed backlog ( 12.7 GW signed contracts, 1.
GTES · Q4 2021 → YESThe question is: Does management give a concrete accounting of where the period's money and effort went, itemizing specific growth-directed uses tied to already real business? YES The transcript shows management itemizing specific growth-directed uses—targeted incremental capacity investments, material science, and innovation—explicitly tied to already-real business: record backlog, book-to-build above 1, strong order rates, and committed wins (e.g., Gogoro, EV platform). These are framed as 2021 spending that consumed profitability and cash flow in Q4, directly supporting demand already arriving rather than future hope. While some operational headwinds (COVID, materials) are noted, the capacity investments are presented as the visible cost of growth underway.
DAN · Q1 2017 → YESThe question is about whether management gives a concrete accounting of where the period's money and effort went, specifically for growth-directed uses tied to already real business. YES Management itemizes concrete uses of the period’s cash and effort: higher capital spending to convert the $175 million backlog (Super Duty, Toyota HiLux, Jeep Wrangler readiness), the $25 million trade-payable settlement tied to the USM acquisition that is already supplying Dana, the Brevini integration costs 8 % organic growth plus aftermarket recovery, and the start-up costs of the new Toledo facility and Hungary gear plant that are supporting committed customer programs already in motion.